Literature DB >> 24486877

Implementation of a chronic unilateral intraparenchymal drug delivery system in a swine model.

Inyong Kim1, Seungleal Paek2, Brian D Nelson3, Emily J Knight4, Michael P Marsh5, Allan J Bieber6, Kevin E Bennet7, Kendall H Lee8.   

Abstract

BACKGROUND: Systemic delivery of pharmacologic agents has led to many significant advances in the treatment of neurologic and psychiatric conditions. However, this approach has several limitations, including difficulty penetrating the blood-brain barrier and enzymatic degradation prior to reaching its intended target. Here, we describe the testing of a system allowing intraparenchymal (IPa) infusion of therapeutic agents directly to the appropriate anatomical targets, in a swine model. NEW
METHOD: Five male pigs underwent 3.0T magnetic resonance (MR) guided placement of an IPa catheter into the dorso-medial putamen, using a combined system of the Leksell stereotactic arc, a Mayo-developed MRI-compatible pig head frame, and a custom-designed Fred Haer Company (FHC) delivery system.
RESULTS: Our results show hemi-lateral coverage of the pig putamen is achievable from a single infusion point and that the volume of the bolus detected in each animal is uniform (1544±420mm(3)). COMPARISON WITH EXISTING
METHOD: The IPa infusion system is designed to isolate the intracranial catheter from bodily-induced forces while delivering drugs and molecules into the brain tissue by convection-enhanced delivery, with minimal-to-no catheter track backflow.
CONCLUSION: This study presents an innovative IPa drug delivery system, which includes a sophisticated catheter and implantable pump designed to deliver drugs and various molecules in a precise and controlled manner with limited backflow. It also demonstrates the efficacy of the delivery system, which has the potential to radically impact the treatment of a wide range of neurologic conditions. Lastly, the swine model used here has certain advantages for translation into clinical applications.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood brain barrier; Central nervous system; Chronic drug delivery system; Intraparenchymal catheter; Swine model

Mesh:

Substances:

Year:  2014        PMID: 24486877      PMCID: PMC4564994          DOI: 10.1016/j.jneumeth.2014.01.029

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  20 in total

Review 1.  Modern methods for delivery of drugs across the blood-brain barrier.

Authors:  Yan Chen; Lihong Liu
Journal:  Adv Drug Deliv Rev       Date:  2011-11-28       Impact factor: 15.470

Review 2.  Potential clinical applications of siRNA technique: benefits and limitations.

Authors:  Shao-Hua Chen; Getu Zhaori
Journal:  Eur J Clin Invest       Date:  2010-10-22       Impact factor: 4.686

3.  Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.

Authors:  John T Slevin; Greg A Gerhardt; Charles D Smith; Don M Gash; Richard Kryscio; Byron Young
Journal:  J Neurosurg       Date:  2005-02       Impact factor: 5.115

Review 4.  Strategies to advance translational research into brain barriers.

Authors:  Edward Neuwelt; N Joan Abbott; Lauren Abrey; William A Banks; Brian Blakley; Thomas Davis; Britta Engelhardt; Paula Grammas; Maiken Nedergaard; John Nutt; William Pardridge; Gary A Rosenberg; Quentin Smith; Lester R Drewes
Journal:  Lancet Neurol       Date:  2008-01       Impact factor: 44.182

5.  Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor.

Authors:  R A Kroll; M A Pagel; L L Muldoon; S Roman-Goldstein; E A Neuwelt
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 6.  The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system.

Authors:  D J Begley
Journal:  J Pharm Pharmacol       Date:  1996-02       Impact factor: 3.765

7.  Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.

Authors:  Yu-Lai Wang; Wanzhao Liu; Etsuko Wada; Miho Murata; Keiji Wada; Ichiro Kanazawa
Journal:  Neurosci Res       Date:  2005-08-10       Impact factor: 3.304

8.  Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model.

Authors:  Oded Singer; Robert A Marr; Edward Rockenstein; Leslie Crews; Nicole G Coufal; Fred H Gage; Inder M Verma; Eliezer Masliah
Journal:  Nat Neurosci       Date:  2005-08-28       Impact factor: 24.884

Review 9.  Huntington's disease: from pathology and genetics to potential therapies.

Authors:  Sara Imarisio; Jenny Carmichael; Viktor Korolchuk; Chien-Wen Chen; Shinji Saiki; Claudia Rose; Gauri Krishna; Janet E Davies; Evangelia Ttofi; Benjamin R Underwood; David C Rubinsztein
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

10.  Nucleus accumbens deep brain stimulation results in insula and prefrontal activation: a large animal FMRI study.

Authors:  Emily J Knight; Hoon-Ki Min; Sun-Chul Hwang; Michael P Marsh; Seungleal Paek; Inyong Kim; Joel P Felmlee; Osama A Abulseoud; Kevin E Bennet; Mark A Frye; Kendall H Lee
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

View more
  2 in total

1.  Acute pressure changes in the brain are correlated with MR elastography stiffness measurements: initial feasibility in an in vivo large animal model.

Authors:  Arvin Arani; Hoon-Ki Min; Nikoo Fattahi; Nicholas M Wetjen; Joshua D Trzasko; Armando Manduca; Clifford R Jack; Kendall H Lee; Richard L Ehman; John Huston
Journal:  Magn Reson Med       Date:  2017-05-09       Impact factor: 4.668

Review 2.  The Relationship Between Dopamine Neurotransmitter Dynamics and the Blood-Oxygen-Level-Dependent (BOLD) Signal: A Review of Pharmacological Functional Magnetic Resonance Imaging.

Authors:  Tyler J Bruinsma; Vidur V Sarma; Yoonbae Oh; Dong Pyo Jang; Su-Youne Chang; Greg A Worrell; Val J Lowe; Hang Joon Jo; Hoon-Ki Min
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.